#AI #Biotechnology #Healthcare
www.forbes.com
How AI Is Transforming Patient Health At Genentech
How is AI transforming the world's original biotech company.
Genentech is an American biotechnology corporation headquartered in South San Francisco, California and celebrating its 50th anniversary this year.
#Biotechnology #FDAApproval #ClinicalTrials
www.nasdaq.com
Weekly Buzz: GSK's Lynavoy Gets FDA Nod; Reproxalap Rejected Again; LNSR Ends Merger Deal
(RTTNews) - This week's biotech landscape witnessed key FDA approvals, rejections, NDA resubmissions, merger terminations, trial discontinuations, and clinical trial data readouts across therapeutic areas such as Turner Syndrome, Late-Line Colorectal Cancer, Obesity, and Type 1 Diabetes.
#Biotechnology #Epilepsy #ConferenceCall
www.benzinga.com
Bright Minds to Announce Topline Results for BMB-101 Phase 2 Trial in Absence Seizures and Developmental and Epileptic Encephalopathies on Tuesday, January 6, 2026 - Bright Minds Biosciences (NASDAQ:DRUG)
- Conference Call and Live Webcast at 8AM ET -
NEW YORK, Jan.
#Osteoporosis #Biotech #ClinicalTrials
www.benzinga.com
Angitia Biopharmaceuticals Completes Enrollment of Phase 2 ARTEMIS Trial Evaluating AGA2118 for the Treatment of Osteoporosis
Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity Newsletter
- Company expects topline data from the study in 2027
WESTLAKE VILLAGE, Calif.
#LeadershipTransition #Biotech #CorporateGovernance
www.benzinga.com
argenx Announces Leadership Transition Marking Next Evolution of Growth - argenx (NASDAQ:ARGX)
Tim Van Hauwermeiren to transition from CEO to Non-Executive Director and Chairman of Board of Directors and Karen Massey to transition from COO to CEO and Executive Director
January 5, 2026 7:00 a.
#Biotech #Pharmaceuticals #FDAApproval
seekingalpha.com
Corcept Therapeutics: Despite FDA Blind Side, Relacorilant Remains A Viable Drug (NASDAQ:CORT)
CORT's strong balance sheet enables pursuit of additional clinical evidence to address the FDA's concerns and potentially secure Relacorilant approval.
